Last reviewed · How we verify
Short-term ON-Q
Short-term ON-Q is a Small molecule drug developed by AdventHealth. It is currently in Phase 1 development.
Short-term ON-Q is not mentioned in the provided facts, but based on the information, ON-Q is related to oligonucleotides, a modality studied in ChEMBL. ON-Q has been studied in clinical trials for various conditions, including infection, sepsis, and NICU/PICU, with interventions involving extended or short-term infusion times of beta-lactam antibiotics.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Short-term ON-Q |
|---|---|
| Sponsor | AdventHealth |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY (NA)
- Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR (PHASE2)
- Short-Term Nutritional Enhancement Combined With Health Education in Postoperative Colorectal Cancer Patients: A Randomized Controlled Trial (NA)
- Sleep Quality in Assisted-Living Residents
- Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis (PHASE4)
- Pain Management After TKA: Comparison of Short- and Long-term Nerve Blocks (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Short-term ON-Q CI brief — competitive landscape report
- Short-term ON-Q updates RSS · CI watch RSS
- AdventHealth portfolio CI
Frequently asked questions about Short-term ON-Q
What is Short-term ON-Q?
Who makes Short-term ON-Q?
What development phase is Short-term ON-Q in?
Related
- Manufacturer: AdventHealth — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing